Seinda Pharma Completes Series A+ Financing to Advance Clinical Development of Ophthalmic Innovative Drug SY-201

Shengyuan Medicine Guangzhou Co., Ltd. Completes Tens of Millions in A+ Round Financing, with Biotech Island Fund (Managed by Guojù Venture Capital) as the Investor; Funds to Be Mainly Used for Clinical Development of Dry Eye Drug SY-201 and Commercial Development of Innovative Products for Rapid Detection of Tear Biomarkers.

Shengyuan Medicine Guangzhou Co., Ltd. is committed to the innovative development of precision diagnosis and treatment in ophthalmology, guided by patient needs, driven by innovation, and focused on Biomarkers. Centering on the molecular mechanisms of diseases, the company is dedicated to developing innovative ophthalmic drugs and precise detection products for ophthalmic Biomarkers, aiming to provide an integrated solution for precision diagnosis and treatment in eye health and visual quality.

Dr. Huang Jingfeng, founder of Shengyuan Medicine Guangzhou Co., Ltd., has over two decades of experience in innovative drug research and clinical development within international pharmaceutical companies. He has extensively studied the molecular mechanisms of immune and ophthalmic diseases, with significant expertise in ophthalmic Biomarker research, authoring more than thirty scientific papers published in journals such as *Science* and *Ophthalmology*. The company has established a big data platform for ophthalmic Biomarker research, providing a crucial foundation for discovering and validating disease molecular mechanisms and new drug targets. This platform continuously supports the original innovation of new drugs and precise detection products for ophthalmic Biomarkers while enhancing the success rate of new drug clinical development, establishing a model for sustainable innovation.

Currently, there are over 1.5 billion dry eye patients globally, with more than 300 million in China. Due to the multiple and complex etiologies and patient heterogeneity, there is an urgent need for precise molecular subtyping and the development of more effective therapeutic drugs. Based on big data of dry eye biomarkers, Shengyuan Medicine Guangzhou Co., Ltd. has discovered new pathogenic molecular mechanisms and successfully developed a dry eye biomarker detection kit, the "α-Lymphotoxin (LTA) Detection Kit." This groundbreaking scientific achievement has been transformed into a clinically valuable, technologically advanced tear diagnostic product that fills a domestic void in China. Meanwhile, SY-201, a new dry eye drug developed based on this novel mechanism, has completed Phase II clinical trials in the United States.

Yang Xi, Chairman of Guojun Venture Capital / General Manager of Guangzhou International Bio Island Co., Ltd., stated: "Since Shengyuan Medicine established itself on Bio Island, we have been following the team's vision and project progress, and have witnessed their persistence and breakthroughs in international innovation within the ophthalmology field. Guojun has always been focused on the ophthalmology sector. By 2025, the domestic dry eye drug market in China is expected to reach $7.2 billion, growing to $20.2 billion by 2030, showing an accelerating growth trend. Shengyuan Medicine’s SY-201, a dry eye drug with dual regulatory submissions in China and the US, has completed Phase II clinical trials in the United States. Recently, Bausch + Lomb's acquisition of Novartis’ dry eye drug Xiidra for $1.75 billion has further heightened our expectations for the global value of SY-201."

Shengyuan Medicine Guangzhou Co., Ltd. completed its first round (Pre-A) financing in 2020 to kickstart new drug research and development, establishing a professional team covering the fields of immunology, ophthalmology, new drug R&D, pharmaceutical sciences, ophthalmic animal models, clinical trials, new drug project management, and registration. In just over two years, the company has built multiple animal models for ophthalmic diseases and developed a robust new drug pipeline; it also swiftly completed the early-stage R&D and Phase II clinical trials in the U.S. for SY-201, its first new drug for dry eye disease. The project won third prize at the finals of the "9th China Innovation and Entrepreneurship Competition."

Guangdong Shengze Kanghua Biomedical Co., Ltd. was established in 2015, focusing on rapid detection products for tear Biomarkers. It became a wholly-owned subsidiary of Shengyuan Medicine in 2020. Shengze Kanghua has successfully developed the world-leading i-ImmunDx® ophthalmic in vitro diagnostic technology and series of products, which were rated as innovative medical devices and selected as one of the "Top Ten Advances in Ophthalmology in China in 2020." The "α-Lymphotoxin (LTA) Detection Kit" and "Total Immunoglobulin E (Total IgE) Detection Kit for Tears" have obtained medical device product registration certificates and entered the commercialization stage, being clinically used in multiple hospitals such as Aier Eye Hospital Group and Huaxia Eye Group. Detection kits for evaluating ocular surface damage and ocular surface inflammation, MMP-9 and IL-6, are also about to enter the market.

Guojv Venture Capital is a wholly-owned private equity fund subsidiary of the High-Tech Zone Group, established in January 2015 with a registered capital of 1 billion yuan, managing and participating in funds with a scale exceeding 3 billion yuan. Guojv Venture Capital serves as an important capital operation platform for the High-Tech Zone Group to strengthen government-enterprise cooperation, industry-finance collaboration, and investment across the entire biopharmaceutical industry chain. Relying on the biomedicine and health industry laid out by the High-Tech Zone Group, it uses "mother fund + investment" as its key approach to deepen the "investment and recruitment linkage" model of "capital chain + industry chain + talent chain," actively promoting investment and business attraction in the biopharmaceutical sector of the Guangzhou Development Zone.